Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.

Birkbak, Nicolai Juul; Kochupurakkal, Bose; Izarzugaza, Jose M G; Eklund, Aron C; Li, Yang; Liu, Joyce; Szallasi, Zoltan; Matulonis, Ursula A; Richardson, Andrea L; Iglehart, J Dirk; Wang, Zhigang C

Birkbak, Nicolai Juul; Kochupurakkal, Bose; Izarzugaza, Jose M G; Eklund, Aron C; Li, Yang; Liu, Joyce; Szallasi, Zoltan; Matulonis, Ursula A; Richardson, Andrea L; Iglehart, J Dirk; Wang, Zhigang C.

Affiliation

Birkbak NJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America ; Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark.

PLoS One ; 8(11): e80023, 2013.

Article in En | MEDLINE | ID: mdl-24265793

Subject(s)

Genes, BRCA1; Genes, BRCA2; Mutation; Ovarian Neoplasms/genetics; Age Factors; Chromosome Aberrations; Drug Resistance, Neoplasm/genetics; Exome; Female; Genome-Wide Association Study; Germ-Line Mutation; Humans; Loss of Heterozygosity; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms/mortality; Ovarian Neoplasms/pathology; Ovarian Neoplasms/therapy; Prognosis; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Genes, BRCA1 / Genes, BRCA2 / Mutation Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2013 Type: Article Affiliation country: Denmark

Fulltext

XML

PubMed Links

Search on Google